MindWalk (NASDAQ:HYFT) Trading 5.8% Higher – Time to Buy?

MindWalk Holdings Corp. (NASDAQ:HYFT) shares rose 5.8% on Friday . The stock traded as high as $1.29 and last traded at $1.27. Approximately 244,976 shares were traded during mid-day trading, an increase of 45% from the average daily volume of 168,838 shares. The stock had previously closed at $1.20.

Analysts Set New Price Targets

A number of research firms recently weighed in on HYFT. HC Wainwright reissued a “buy” rating on shares of MindWalk in a research note on Friday, March 13th. UBS Group reissued a “buy” rating on shares of MindWalk in a research note on Friday, March 13th. Zacks Research raised shares of MindWalk from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Weiss Ratings began coverage on shares of MindWalk in a research note on Wednesday, January 14th. They set a “sell (d-)” rating for the company. Finally, JonesTrading began coverage on shares of MindWalk in a research note on Thursday, April 16th. They set a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.00.

MindWalk Stock Up 5.8%

The stock has a market cap of $58.62 million, a PE ratio of -6.35 and a beta of 0.65. The stock’s fifty day moving average is $1.19. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.64 and a current ratio of 3.74.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.50 million. MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%. As a group, equities research analysts predict that MindWalk Holdings Corp. will post -0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in shares of MindWalk by 8.4% in the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after buying an additional 18,600 shares during the period. Bank of Montreal Can boosted its holdings in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after buying an additional 24,500 shares during the period. Virtu Financial LLC acquired a new position in shares of MindWalk in the fourth quarter valued at approximately $51,000. XTX Topco Ltd boosted its holdings in shares of MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after buying an additional 44,331 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new position in shares of MindWalk in the fourth quarter valued at approximately $91,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.